Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term,...

Area of Science:

• Neurology
• Cardiology

Background:

• Cardiovascular (CV) risk factors can restrict migraine treatment choices.
• Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, does not cause vasoconstriction.
• Assessing rimegepant's safety in patients with varying CV risk is crucial.

Purpose of the Study:

• To evaluate the safety and tolerability of rimegepant in adult migraine patients with pre-existing cardiovascular risk factors.
• To analyze safety data based on the number of CV risk factors and Framingham Risk Score.

Main Methods:

• A phase II/III open-label safety study involved 1800 participants treating migraine with rimegepant 75 mg orally for up to 52 weeks.
• Participants with uncontrolled, unstable, or recent CV disease were excluded.
• Safety was assessed in subgroups based on CV risk factors (0, 1, ≥2) and Framingham Risk Score (<10%, ≥10%).

Main Results:

• Adverse event (AE) and serious AE proportions were consistent across CV risk subgroups.
• AEs leading to discontinuation were low across all risk categories.
• The safety profile of rimegepant remained favorable regardless of cardiovascular risk level.

Conclusions:

• Rimegepant demonstrates favorable safety and tolerability in adults with migraine and cardiovascular risk factors.
• The drug is suitable for patients with moderate to high cardiovascular risk.
• This supports rimegepant as a viable migraine treatment option for a broader patient population.